HekaBio and Namier Capital Forge Strategic Healthcare Partnership to Fast-Track UK and European Innovation into the Japanese Market
Landmark bilateral agreement unites Namier's corporate finance network with HekaBio's in-licensing expertise and fully licensed regulatory engine across biopharma and MedTech.
TOKYO & LONDON — September 2026
HekaBio, a Tokyo-based biotech and MedTech development and commercialisation platform, and Namier Capital a UK corporate finance firm, today announced a powerful strategic partnership set to accelerate cross-border expansion for high-impact healthcare innovations.
The alliance establishes a decisive bilateral bridge between the UK/Europe and Japan, spanning key therapeutic areas including oncology, central nervous system (CNS) disorders and rare diseases, and covering both innovative biopharmaceuticals and medical devices.
Under the agreement, Namier Capital will harness its corporate finance network to identify growth-stage life science assets seeking entry into Asia. HekaBio acts as the operational execution partner in Japan, with deep expertise in in-licensing foreign innovations and driving them through clinical development, regulatory approval and the key opinion leader (KOL) engagement essential to nationwide adoption.
HekaBio brings a proven track record of securing Japanese PMDA approvals and holds business licences across all four major healthcare regulatory categories: Pharmaceuticals, Medical Devices, In-Vitro Diagnostics (IVDs) and Regenerative Medicine. Operating with its experienced in-house regulatory team, HekaBio serves as the Designated Marketing Authorisation Holder (DMAH) and importer of record, de-risking and powering the entire approval process for foreign assets entering the Japanese healthcare system.
"Navigating PMDA approvals and securing the right in-licensing framework in Japan demands deep local execution," said Rob Claar, Co-founder & CEO of HekaBio. "By pairing Namier's venture-building expertise with our fully licensed infrastructure and proven regulatory track record in Tokyo, we give global innovators a direct, tried-and-tested route to approval and commercialisation in the world's second-largest developed healthcare market."
"This partnership with HekaBio directly advances our mission to back clinically validated, high-impact technologies," added Stewart McCrone, Head of Healthcare at Namier Capital. "HekaBio's regulatory execution and local network mean our portfolio companies can move swiftly and confidently to secure Japanese regulatory pathways and clinical adoption."
The collaboration also opens the door for promising Japanese biopharma and MedTech innovations to access Western capital, strategic partners and market networks across the UK, Europe and North America.
About HekaBioHekaBio is a Tokyo-based healthcare development and commercialisation platform dedicated to bringing global life science innovations into Japan through in-licensing, clinical development and PMDA regulatory execution. With complete licensing coverage across pharmaceuticals, medical devices, IVDs and regenerative medicine, HekaBio manages end-to-end regulatory oversight, DMAH representation and Japanese market deployment.
About Namier Capital Namier Capital is a UK corporate finance firm operating across a range of sectors, of which healthcare and planetary-health technologies are key focuses. Led by senior industry veterans, Namier provides strategic advisory services to growth-stage companies in its chosen areas of expertise.
